New blood test could replace painful biopsies for breast cancer patients

NCT ID NCT04480814

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new blood test (liquid biopsy) that looks for cancer DNA in the blood of 30 women with advanced ER+/HER2- breast cancer. The goal was to see if the test can accurately find cancer mutations without needing a traditional tissue biopsy. The results will help doctors monitor cancer changes over time with a simple blood draw.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Oct 2019

Finished

Feb 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

120 with metastatic breast cancer 30 healthy subjects

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female aged ≥ 18 years of age. 2. Histological confirmed ER+/HER2- metastatic Breast Cancer prior to beginning a treatment 3. Life expectancy permits participation to the study. 4. Available tumor tissue sample for molecular analysis. 5. Signed informed consent form. Exclusion Criteria: 1. Female younger than 18 years old. 2. History of another malignancy within 3 years or current 2nd primary malignancy. 3. Patients that have not signed the informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aretaieio University Hospital of Athens

    Athens, Attica, 11528, Greece

  • Metropolital Hospital

    Piraeus, Piraeus, 18547, Greece

  • University General Hospital of Alexandroupoli

    Alexandroupoli, Alexandroupolis, 68100, Greece

  • University General Hospital of Athens Attikon

    Athens, Attica, 124 62, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.